Grant: Project Grant
Centre for Addiction and Mental Health (Toronto)
$711,450.00
Development of in vivo PET imaging methods using SV2A PET to evaluate synapse damages in multiple sclerosis
FY 2025-26
Summary
Multiple sclerosis (MS) is a long-lasting disease that affects the brain and spinal cord in predominantly young adults. It can lead to problems associated with movement and thinking. Canada has one of the highest rates of MS, with an estimated 133,635 cases projected by 2031. Currently, over 2.8 million people globally are living with MS, and it places a significant burden on the healthcare system. The exact cause of MS remains unclear nor is a cure or
simple diagnostic test available. We aim to address this limitation by using a new imaging method called PET imaging, that specifically targets a protein called SV2A. This method can help us monitor changes in the connections between nerve cells over the course of the disease. Studies have shown that SV2A levels decrease in the brains and spinal cords of MS patients as well as in mouse models of the disease. This suggests that SV2A PET imaging could become a sensitive and reliable tool for diagnosing and monitoring MS. Our research will focus on developing and testing this new imaging method to help scientists and doctors better understand, diagnose, and predict the outcomes of MS in human patients.
Department
Program
Project Grant
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
533456
Name
Zheng Chao
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Medical Physics & Imaging
Projecttitle
Development of in vivo PET imaging methods using SV2A PET to evaluate synapse damages in multiple sclerosis
Programtype2
Operating Grants
Orgnameinp2
Centre for Addiction and Mental Health (Toronto)
Cihramount2
$711,450
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Assess Therapeutic Effects; Autoradiograph; Disease Detection; Longitudinal Study; Multiple Sclerosis; Pet Imaging; Radiopharmaceuticals; Synaptic Density; Synaptic Vesicle Glycoprotein 2a (Sv2a)
Abstract
Multiple sclerosis (MS) is a long-lasting disease that affects the brain and spinal cord in predominantly young adults. It can lead to problems associated with movement and thinking. Canada has one of the highest rates of MS, with an estimated 133,635 cases projected by 2031. Currently, over 2.8 million people globally are living with MS, and it places a significant burden on the healthcare system. The exact cause of MS remains unclear nor is a cure or
simple diagnostic test available. We aim to address this limitation by using a new imaging method called PET imaging, that specifically targets a protein called SV2A. This method can help us monitor changes in the connections between nerve cells over the course of the disease. Studies have shown that SV2A levels decrease in the brains and spinal cords of MS patients as well as in mouse models of the disease. This suggests that SV2A PET imaging could become a sensitive and reliable tool for diagnosing and monitoring MS. Our research will focus on developing and testing this new imaging method to help scientists and doctors better understand, diagnose, and predict the outcomes of MS in human patients.
Competitiondate
202509
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Zheng, Chao
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $711,450~ $0~
